Diabetic Foot Ulcer Market to Grow with Advancements in Treatment
The diabetic foot ulcer market was valued at approximately USD 2.5 billion in 2025. A report forecasts a 10% annual growth rate through 2036, driven by new treatments and clinical innovations.
Albany, New York – October 07, 2026 – The market for diabetic foot ulcers (DFUs) is on a growth trajectory, with significant expansion projected through 2036. A new report by DelveInsight estimates the market size at approximately USD 2.5 billion in 2025. Between 2026 and 2036, the market is expected to grow at a compound annual growth rate (CAGR) of 10 percent.
This growth is underpinned by advancements in treatment methodologies and clinical innovation. In September 2026, PolarityBio received FDA acceptance for its SkinTE therapy for Wagner Grade 1 diabetic foot ulcers. Simultaneously, Lakewood-Amedex initiated a Phase IIa study for topical Nu-3 in mildly infected ulcers.
Further developments include the commencement of Applied Biologics' Phase III BIOxHEAL trial for chronic DFUs, FibroBiologics launching a Phase 1/2 trial for CYWC628, and positive results reported for Celularity Inc.'s PDA-002 therapy, published in the International Wound Journal.
The United States represents the largest segment of the market, estimated at USD 2.3 billion in 2025. The sector's evolution indicates a shift from conventional wound care approaches towards advanced regenerative and antimicrobial therapies, addressing a significant unmet medical need.